BUSINESS
62% Indians hesitant to get COVID-19 vaccine shot: LocalCircles survey
As per LocalCircles, the COVID-19 vaccine survey is based on 17,000 responses received from citizens residing in 230 districts of India.
BUSINESS
Around 3.81 lakh people vaccinated, govt says no cases of serious AEFI linked to vaccine found till date
So far, around 580 cases of AEFI have been reported, of which there were seven cases of hospitalisation.
BUSINESS
Why Johnson & Johnson's Covid-19 vaccine is generating a lot of interest
Initial reports indicate the vaccine elicits a very good response. The single-dose vaccine can prove to be a gamechanger, especially in a country with a large population, such as India, where two doses will consume tremendous resources
BUSINESS
Pharma wrap: India rolls out COVID-19 vaccination of healthcare workers, needs to address technical glitches, vaccine hesitancy
Moneycontrol spoke to couple of doctors who received Covid-19 vaccine shot. All of them expressed satisfaction on the way things went.
BUSINESS
What is informed consent form for Bharat Biotech Covaxin, what information is sought in the form and other questions answered
..people who receive the vaccine will have to sign a three-page informed consent form, and will also be monitored for any serious side effects.
BUSINESS
Explained | COVID-19 vaccination drive: How to register, who will get the shots first and other queries answered
In the initial phase, the government said it would inoculate about one crore healthcare workers. This will be followed by two crore frontline workers, police, armed forces, municipal workers, revenue staff and others.
BUSINESS
Here are 10 things to know about SII's Covishield vaccine from package insert & factsheet
The package insert and factsheet the comes with the vaccine includes information on indications and usage, dosage strength, clinical efficacy, contraindications, risks and benefits, and use in specific populations.
BUSINESS
Dr Reddy's gets DSMB nod to conduct Phase-3 trial of Sputnik Covid-19 vaccine in India
The phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India. The DSMB concluded that no safety concerns were identified and the study has met the primary endpoints of safety, Dr Reddy's said.
BUSINESS
Pharma wrap: Why Bharat Biotech's Covaxin trial site in Bhopal is stirring up controversy
There were allegations of certain violations in the Phase-III clinical trial taking place at People’s College of Medical Sciences and Research Centre in Bhopal to assess the efficacy and safety of the vaccine.
BUSINESS
PM's scientific advisor says current vaccines offer immunity against Covid-19 for at least a year
"The expectation is that the immunity due to the vaccines will be significantly long, certainly we think over a year, but how long we don't know," VijayRaghavan said addressing questions on Covid-19 vaccines.
BUSINESS
Government to give priority to suppliers sourcing maximum local input materials in procurement of medicines
A Class-I supplier will use local content equal to or more than 80 percent, Class-II supplier use 50-80 percent of local content and Non-Local supplier will use less than 50 percent. Class-I and Class-II suppliers will get higher priority.
BUSINESS
Bharat Biotech completes enrolment of 25,800 volunteers for phase-3 trial of Covaxin
Bharat Biotech expects the administration of the second dose of Covaxin by February-March, said Chairman and Managing Director Krishna Ella.
BUSINESS
Here are 10 things to know about Bharat Biotech, its founder Krishna Ella
Ella said Bharat Biotech is investing Rs 100 crore on research and conducting clinical trials in FY2021. In addition, the company will invest up to Rs 200 crore in FY2021 and FY2022 for the development of a greenfield facility for a Covid-19 vaccine.
BUSINESS
Here’s how SII’s Covishield and Bharat Biotech’s Covaxin stack up against each other
How safe are the vaccines, how many doses do you need to take, what is the duration between doses, what is the price of the vaccines, which countries have approved them… Read on to get the answers to these and other questions.
BUSINESS
Panel reviewed Bharat Biotech Covaxin in the absence of efficacy data, show minutes of SEC meeting
The minutes of the SEC meeting show that the panel had asked Bharat Biotech to expedite the recruitment for phase-3 trials and perform interim efficacy analysis, even as it recommended the restricted emergency use of Covaxin on January 1.
BUSINESS
DCGIs asks Bharat Biotech to submit protocol for administering COVID-19 vaccine under clinical trial mode
The clinical trial mode means, that everyone will consent for the vaccine, there will be no placebo arm and the recipients will be closely monitored, said ICMR's Balram Bhargava.
BUSINESS
Explained: Why conditional approval for Bharat Biotech’s Covaxin is raising questions
The DCGI has said the approval is in “clinical trial mode” but has not clarified this in detail. If an experimental vaccine is given to people, there should be informed consent explaining the potential risks and benefits of the vaccine and post-vaccination follow-up. In case there is any serious adverse reaction, the recipient may also be eligible for compensation.
BUSINESS
Coronavirus vaccine India | Covaxin offers protection against mutant COVID-19 strains, says Bharat Biotech, ICMR
Bharat Biotech said the evaluation of its coronavirus vaccine Covaxin has resulted in several unique product characteristics including long term persistence of immune responses to multiple viral proteins, as opposed to only the spike protein, and has demonstrated broad spectrum neutralizing capability with heterologous SARS-CoV2 strains, thus potentially reducing or eliminating escape mutants.
BUSINESS
Explained | SII's COVID-19 vaccine: What is emergency approval, what does the data show, what next after clearance and more
The Subject Expert Committee of the Central Drugs Standard Control Organisation is also reviewing the emergency use applications of Bharat Biotech and Pfizer.
BUSINESS
Serum Institute of India to have 100 million COVID-19 vaccine doses ready by January first week
The Indian government is planning to vaccinate 300 million people in the first wave of vaccination. The first phase will target 10 million frontline health workers by February.
BUSINESS
Will normalcy return to COVID-hit Indian pharmaceutical market in 2021?
The pharmaceutical sector is expecting sales to normalise by the second half of 2021, with the availability of COVID-19 vaccine and coronavirus receding.
BUSINESS
Explained: What are VLP-based Covid-19 vaccines, and why is the platform attracting vaccine cos?
Two VLP vaccines have reached the clinical trial stage. Canadian biotech firm Medicago, backed by tobacco behemoth Phillip Morris, vaccine candidate based on VLP has reached phase 2/3 trial.
BUSINESS
ICMR chief says non-judicious use of therapies against Covid will lead to immune pressure on virus
"It is important from the scientific community perspective that we do not put too much immune pressure on the virus; we have to maintain the judicious use of therapies, which are going to benefit," Bhargava explained.
BUSINESS
Biological E raises $5 million from CEPI to scale up production of COVID-19 vaccine
CEPI will also explore providing additional funds to BE with the goal of potentially enabling the production of 100 million doses in 2021.
